Pharma BD Deal Intelligence
A savvy tuck-in: Beckman Coulter paid $138M for DSL, a specialty immunoassay maker with just $34M in 2004 sales but ~15% growth, betting DSL plus Agencourt would add $40-50M of incremental revenue in 2006 — a rich multiple on a small business.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Beckman Coulter agreed to acquire DSL for ~$138M, calling the deal a way to 'broaden our immunoassay menu and strategically advance our already successful…
Industry coverage characterized the DSL purchase as a 'savvy' tuck-in that strengthened Beckman Coulter's immunoassay business by adding proprietary…
Management said DSL plus Agencourt were expected to add $40-$50M of incremental revenue in 2006, fitting the 10%+ consumables growth target and broadening the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Beckman Coulter acquires DSL for $138M; specialty immunoassays for reproductive endocrinology and cardiovascular risk.
$5.0B Global immunoassay market (2005); endocrinology ~10% segment · ~$34M DSL 2004 revenue
Specialty endocrine immunoassays measure hormones critical to fertility assessment, ovarian reserve, and pregnancy risk stratification. DSL's franchise centered on Inhibin A/B, anti-Mullerian hormone (AMH), and PAPP-A — markers used by reproductive endocrinologists, ob-gyns, and cardiovascular labs to quantify ovarian function, screen for trisomies, and assess cardiac event risk.
The 2005 immunoassay market was a ~$5B global category dominated by Roche Diagnostics, Abbott (AxSYM/Architect), Siemens (ADVIA Centaur, post-Bayer/Dade Behring), and Beckman Coulter (Access). Specialty endocrinology — roughly 10% of the market and growing ~15%/year per Beckman — was contested by DSL, Diagnostic Products Corp (DPC, later Siemens), and Bayer Diagnostics. DSL's differentiator was its proprietary Inhibin A/B and AMH assays for ovarian reserve testing plus exclusive PAPP-A rights for cardiovascular risk and Down syndrome screening. The deal let Beckman bolt high-margin proprietary content onto its installed Access immunoassay base, attacking DPC's legacy lock on fertility hormone testing and giving Beckman a credible reproductive endocrinology menu without years of internal R&D. For OB labs and IVF clinics, the consolidation tightened single-vendor menu coverage; for Roche and Abbott, it raised the bar in a niche they had under-prioritized. Per BioSpace 2005 results commentary, DSL plus Agencourt were expected to add $40-50M of incremental 2006 revenue. Source: https://www.biospace.com/beckman-coulter-inc-announces-fourth-quarter-and-year-end-results-for-2005
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Beckman Coulter Inc. / Diagnostic Systems Laboratories Corporation (DSL) (this deal) | 2005 | $138M | — |
| Beckman Coulter Inc. / Lumigen Inc. | 2006 | $185M | 69 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2005 deals